EIP
TAK icon

Ellis Investment Partners’s Takeda Pharmaceutical TAK Stock Holding History

Ellis Investment Partners’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-60
Closed – – 680
2022
Q3 		$0 Buy
+60
New +$834 ﹤0.01% 826
2021
Q2 		– Sell
-110
Closed -$2K – 793
2021
Q1 		$2K Hold
110
– – ﹤0.01% 732
2020
Q4 		$2K Hold
110
– – ﹤0.01% 697
2020
Q3 		$1K Hold
110
– – ﹤0.01% 703
2020
Q2 		$1K Hold
110
– – ﹤0.01% 689
2020
Q1 		$1K Hold
110
– – ﹤0.01% 694
2019
Q4 		$2K Hold
110
– – ﹤0.01% 646
2019
Q3 		$1K Hold
110
– – ﹤0.01% 682
2019
Q2 		$1K Buy
+110
New +$2K ﹤0.01% 642

Other funds holding TAK

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.69B AUM
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Ellis Investment Partners's TAK Position: Q4 2022 in Review

Ellis Investment Partners sold out of Takeda Pharmaceutical (TAK) in Q4 2022, closing a stake of 60 shares.

Ellis Investment Partners first reported a position in TAK in Q2 2019 and held it in 9 quarters. The position peaked at $2K in Q1 2021. 281 funds tracked by Wall St. Rank hold TAK as of Q4 2022.

  • Ellis Investment Partners reported no remaining Takeda Pharmaceutical position as of Q4 2022 after selling out during the quarter.
  • Ellis Investment Partners sold 60 Takeda Pharmaceutical shares in Q4 2022.
  • Ellis Investment Partners first reported a position in Takeda Pharmaceutical in Q2 2019 and held it in 9 quarters.
  • Ellis Investment Partners's Takeda Pharmaceutical position peaked at $2K in Q1 2021.
  • 281 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q4 2022.

Based on Ellis Investment Partners's 13F filing for Q4 2022, filed 31 Jan 2023.